All Outputs (59)

AZD5363 plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (PAKT): A randomised, double-blind, placebo-controlled, phase II trial (2018)
Presentation / Conference
Schmid, P., Abraham, J., Chan, S., Wheatley, D., Brunt, M., Nemsadze, G., …Turner, N. C. (2018, June). AZD5363 plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (PAKT): A randomised, double-blind, placebo-controlled, phase II trial. Presented at 2018 ASCO Annual Meeting I, Chicago, IL, USA

Background: The PI3K/AKT signalling pathway is frequently activated in triple-negative breast cancer (TNBC). AZD5363 is a highly-selective, oral, small molecule AKT inhibitor. The PAKT trial investigated the addition of AZD5363 to paclitaxel as 1st-l... Read More about AZD5363 plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (PAKT): A randomised, double-blind, placebo-controlled, phase II trial.

Systematic review of the impact of breast-conserving surgery on cancer outcomes of multiple ipsilateral breast cancers. (2018)
Journal Article
Winters, Z. E., Horsnell, J., Elvers, K. T., Maxwell, A. J., Jones, L. J., Shaaban, A. M., …Brunt, A. M. (2018). Systematic review of the impact of breast-conserving surgery on cancer outcomes of multiple ipsilateral breast cancers. BJS Open, 2(4), 162 - 174. https://doi.org/10.1002/bjs5.53

Background: The clinical effectiveness of treating ipsilateral multifocal (MF) and multicentric (MC) breast cancers using breast-conserving surgery (BCS) compared with the standard of mastectomy is uncertain. Inconsistencies relate to definitions, in... Read More about Systematic review of the impact of breast-conserving surgery on cancer outcomes of multiple ipsilateral breast cancers..

Radioactive Phosphorous (P32) Leukomogenic and Oncogenic Risk Stratification (2018)
Presentation / Conference
Fullagar, A., Sodhi, L., Pillai, S., & Brunt, A. (2018, April). Radioactive Phosphorous (P32) Leukomogenic and Oncogenic Risk Stratification. Paper presented at 58th Annual Scientific Meeting of the British-Society-for-Haematology, Liverpool, UK

Meeting abstract

FAST-Forward phase 3 RCT of 1-week hypofractionated breast radiotherapy: 3-year normal tissue effects (2018)
Journal Article
Brunt, A., Haviland, J., Sydenham, M., Al-hasso, A., Bloomfield, D., Chan, C., …Yarnold, J. (2018). FAST-Forward phase 3 RCT of 1-week hypofractionated breast radiotherapy: 3-year normal tissue effects. Radiotherapy and Oncology, 127(S1), S311 -S312. https://doi.org/10.1016/S0167-8140%2818%2930905-8

Meeting abstract.

Benefits in early use of eribulin in metastatic breast cancer: A 7-year UHNM experience (2018)
Presentation / Conference
Yoganayagam, N., Tripathy, A., Exton, S., Rawet, T., Wu, K., Brunt, A., …Jegannathen, A. (2018, March). Benefits in early use of eribulin in metastatic breast cancer: A 7-year UHNM experience. Paper presented at THE 11TH EUROPEAN BREAST CANCER CONFERENCE, Barcelona, Spain

Meeting abstract from 11th European Breast Cancer Conference (EBCC), Barcelona, Spain, Mar 21-23, 2018.

MANTA - A randomized phase II study of fulvestrant in combination with the dual mTOR inhibitor AZD2014 or everolimus or fulvestrant alone in estrogen receptor-positive advanced or metastatic breast cancer (2017)
Presentation / Conference
Schmid, P., Zaiss, M., Harper-Wynne, C., Ferreira, M., Dubey, S., Chan, S., …Cortes Castan, J. (2017, December). MANTA - A randomized phase II study of fulvestrant in combination with the dual mTOR inhibitor AZD2014 or everolimus or fulvestrant alone in estrogen receptor-positive advanced or metastatic breast cancer. Paper presented at 2017 San Antonio Breast Cancer Symposium, San Antonio, Texas

Background: Resistance to endocrine therapy remains a major clinical challenge with aberrant PI3K/ mTOR pathway activation being one of the main drivers. Randomised clinical trials have demonstrated a substantial benefit of adding everolimus to endoc... Read More about MANTA - A randomized phase II study of fulvestrant in combination with the dual mTOR inhibitor AZD2014 or everolimus or fulvestrant alone in estrogen receptor-positive advanced or metastatic breast cancer.

Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. (2017)
Journal Article
Coles, C. E., Griffin, C. L., Kirby, A. M., Titley, J., Agrawal, R. K., Alhasso, A., …Bliss, J. M. (2017). Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. The Lancet, 390(10099), 1048 - 1060. https://doi.org/10.1016/S0140-6736%2817%2931145-5

BACKGROUND: Local cancer relapse risk after breast conservation surgery followed by radiotherapy has fallen sharply in many countries, and is influenced by patient age and clinicopathological factors. We hypothesise that partial-breast radiotherapy r... Read More about Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial..

Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial (2017)
Journal Article
Cameron, D., Morden, J. P., Canney, P., Velikova, G., Coleman, R., Bartlett, J., …Bliss, J. M. (2017). Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial. Lancet Oncology, 18(7), 929 - 945. https://doi.org/10.1016/S1470-2045%2817%2930404-7

Background
Adjuvant chemotherapy for early breast cancer has improved outcomes but causes toxicity. The UK TACT2 trial used a 2×2 factorial design to test two hypotheses: whether use of accelerated epirubicin would improve time to tumour recurrence... Read More about Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial.

Partial breast radiotherapy after breast conservation: 5 year outcomes from the IMPORT LOW (CRUK/06/003) phase III trial (2017)
Presentation / Conference
Coles, C., Griffin, C., Kirby, A., Agrawal, R., Alhasso, A., Bhattacharya, I., …Bliss, J. (2017, May). Partial breast radiotherapy after breast conservation: 5 year outcomes from the IMPORT LOW (CRUK/06/003) phase III trial. Paper presented at ESTRO 36, Vienna, Austria

Conference abstract. Part of special issue:
ESTRO 36, May 5-9, 2017, Vienna, Austria.

Evaluating variability of contouring using ESTRO guidelines for elective breast cancer radiotherapy (2017)
Journal Article
Brunt. (2017). Evaluating variability of contouring using ESTRO guidelines for elective breast cancer radiotherapy. Radiotherapy and Oncology, 123(S1), S136 - S137. https://doi.org/10.1016/S0167-8140%2817%2930708-9

Conference abstract. part of Special Issue ESTRO 36, May 5-9, 2017, Vienna, Austria.

Bone Mineral Density Screening in Invasive Breast Cancer Patients Treated with Anastrozole in Adjuvant Setting (2017)
Journal Article
Pai, K., Gilani, S., & Brunt, A. (2017). Bone Mineral Density Screening in Invasive Breast Cancer Patients Treated with Anastrozole in Adjuvant Setting. Clinical Oncology, 29(6), e102 - e103. https://doi.org/10.1016/j.clon.2017.01.031

Trastuzumab infusion reactions in breast cancer. Should we routinely observe after the first dose? (2017)
Report
Price, L., & Brunt, A. M. (2017). Trastuzumab infusion reactions in breast cancer. Should we routinely observe after the first dose?

Trastuzumab (Herceptin) is used in neoadjuvant, adjuvant and metastatic breast cancer. Infusion reactions are a common side effect most of which are mild and easily managed, anaphylaxis occurs rarely. The summary of product characteristics recommends... Read More about Trastuzumab infusion reactions in breast cancer. Should we routinely observe after the first dose?.

Acute skin toxicity associated with a 1-week schedule of whole breast radiotherapy compared with a standard 3-week regimen delivered in the UK FAST-Forward Trial (2016)
Journal Article
Brunt, A. M., Wheatley, D., Yarnold, J., Somaiah, N., Kelly, S., Harnett, A., …Bliss, J. M. (2016). Acute skin toxicity associated with a 1-week schedule of whole breast radiotherapy compared with a standard 3-week regimen delivered in the UK FAST-Forward Trial. Radiotherapy and Oncology, 120(1), 114-118. https://doi.org/10.1016/j.radonc.2016.02.027

BACKGROUND AND PURPOSE: FAST-Forward is a phase 3 clinical trial testing a 1-week course of whole breast radiotherapy against the UK standard 3-week regimen after primary surgery for early breast cancer. Two acute skin toxicity substudies were undert... Read More about Acute skin toxicity associated with a 1-week schedule of whole breast radiotherapy compared with a standard 3-week regimen delivered in the UK FAST-Forward Trial.

Comparison of CT-volumed supraclavicular fossa radiotherapy planning and conventional simulator-planned defined by bony landmarks for early breast cancer (2016)
Journal Article
Brunt, A. M., Lupton, S., Thorley, K., Pearce, L., & Handley, J. (2016). Comparison of CT-volumed supraclavicular fossa radiotherapy planning and conventional simulator-planned defined by bony landmarks for early breast cancer. Reports of Practical Oncology and Radiotherapy, 21(3), 219-224. https://doi.org/10.1016/j.rpor.2016.02.004

Aim
A comparison of techniques, CT planning of the supraclavicular fossa and field based simulation. We highlight CT planned SCF radiotherapy which would be useful for a centre introducing the technique.

Background
Development of radiotherapy te... Read More about Comparison of CT-volumed supraclavicular fossa radiotherapy planning and conventional simulator-planned defined by bony landmarks for early breast cancer.

Time for a randomised clinical trial evaluating breast conserving surgery compared to mastectomy in ipsilateral mutlifocal breast cancer (MFBC)? (2016)
Journal Article
Winters, Z., Horsnell, J., Schmid, P., Jones, J., Shaaban, A., Maxwell, A., …Management Group, M. T. (2016). Time for a randomised clinical trial evaluating breast conserving surgery compared to mastectomy in ipsilateral mutlifocal breast cancer (MFBC)?. Breast, 26, 149-150. https://doi.org/10.1016/j.breast.2015.12.011

Partial breast radiotherapy for women with early breast cancer: First results of local recurrence data for IMPORT LOW (CRUK/06/003) (2016)
Presentation / Conference
Coles, C., Agrawal, R., Ah-See, M., Algurafi, H., Alhasso, A., Brunt, A., …Bliss, J. (2016, March). Partial breast radiotherapy for women with early breast cancer: First results of local recurrence data for IMPORT LOW (CRUK/06/003). Paper presented at 10th European Breast Cancer Conference (EBCC-10)

Background: IMPORT LOW is a randomised, multi-centre phase III trial testing partial breast radiotherapy (RT) using intensity modulated RT in women with low risk early stage breast cancer, for whom late complications of RT are the dominant hazard rat... Read More about Partial breast radiotherapy for women with early breast cancer: First results of local recurrence data for IMPORT LOW (CRUK/06/003).

2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial (2013)
Journal Article
MD, P. A. G., PhD, P. R. D. G., MD, P. M. J. P., MD, E. D. A., MSci, M. P., MD, P. T. M. S., …MD †, P. J. B. (2013). 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. The Lancet, 382(9897), 1021-1028. https://doi.org/10.1016/S0140-6736%2813%2961094-6

Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial (2013)
Journal Article
RD Johnston, S., Kilburn, L. S., Ellis, P., Dodwell, D., Cameron, D., Hayward, L., …investigators, S. (2013). Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial. Lancet Oncology, 14(10), 989-998. https://doi.org/10.1016/S1470-2045%2813%2970322-X

Breast Radiotherapy: Less is More? (2012)
Journal Article
Coles, C. E., Brunt, A. M., Wheatley, D., Mukesh, M. B., & Yarnold, J. R. (2013). Breast Radiotherapy: Less is More?. Clinical Oncology, 25(2), 127-134. https://doi.org/10.1016/j.clon.2012.10.013